secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008477
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Reports Q1 2022 Financial Results, Provides Clinical Updates for Evorpacept
--------------------------------------------------------------------------------

- First patient dosed in Phase 2/3 ASPEN-06 study evaluating evorpacept in HER2-positive gastric/GEJ cancer.
- FDA granted Orphan Drug Designation to evorpacept for treatment of gastric/GEJ cancer.
- Cash, cash equivalents and investments totaled $341.7 million as of March 31, 2022, expected to fund operations through mid-2024.
- GAAP net loss for Q1 2022 was $24.5 million ($0.60 per share), compared to $14.2 million ($0.35 per share) in Q1 2021.
- Appointed Itziar Canamasas, Ph.D. to its Board of Directors in April 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022008477/0000950170-22-008477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022008477/alxo-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer